Clik here to view.
Samsung Bioepis Announces Phase 3 Results of SB8, Bevacizumab Biosimilar...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced results from the Phase 3 study evaluating the efficacy and safety of SB8, a bevacizumab biosimilar candidate, compared to reference...
View ArticleClik here to view.
Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib...
WILMINGTON, Del. Incyte (Nasdaq:INCY) announces updated results, including the final result for the primary endpoint, from its Phase 2 FIGHT-202 trial evaluating pemigatinib, a selective fibroblast...
View ArticleClik here to view.
CORRECTING and REPLACING Incyte Announces Positive Updated Results from Phase...
WILMINGTON, Del. Sixth paragraph, fourth sentence of release should read: Serous retinal detachment was observed in 4 percent of patients (Grade ≥3, 1 percent) with none of the cases resulting in...
View ArticleClik here to view.
インサイト、白斑患者でルキソリチニブ・クリームを評価する第3相臨床試験プログラムで最初の患者が治療を受けたと発表
米デラウェア州ウィルミントン （ビジネスワイヤ） — インサイト（Nasdaq:INCY）は本日、第3相TRuE-V臨床試験プログラムで最初の患者が治療を受けたと発表しました。本プログラムは、白斑の青年・成人患者（年齢12歳以上）に対する単剤療法としてのルキソリチニブ・クリームの安全性と有効性を評価するものです。...
View ArticleClik here to view.
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of...
TOKYO & BOTHELL, Wash. Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced initial results from the...
View ArticleClik here to view.
CAP Laboratory Accreditation Program Expands Inspector Training Footprint in...
TOKYO The College of American Pathologists (CAP) and CGIkk hosted laboratory accreditation inspector training for 20 pathologists from leading institutions across Japan. The September 28 training...
View ArticleClik here to view.
三叶草生物制药在研1类新药SCB-313中国恶性腹水I期临床完成首例患者给药
成都 (美国商业资讯)–三叶草生物制药，一家致力于创新及变革性生物药物研发的生物制药公司，今天宣布在中国进行的另一项SCB-313 I期临床试验完成首例患者给药。SCB-313是一种创新重组人肿瘤坏死因子相关凋亡诱导配体（TRAIL）-...
View ArticleClik here to view.
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in...
CHENGDU, China Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in another Phase...
View ArticleClik here to view.
CAP検査室認定プログラムが日本で審査員研修の参加機関を拡大
東京 （ビジネスワイヤ） — 米国病理医協会（CAP）とCGIkkは、日本の有力機関に所属する病理医20人を対象とする検査室認定審査員研修を開催しました。9月28日の研修は、CAPに代わって検査室を認定する審査員を地域でさらに増やし、検査室の質と正確性を確保して患者ケアを改善する上で、最初の取り組みとなります。...
View ArticleClik here to view.
アビオメッド、低侵襲の順行性心臓ポンプSmartAssist搭載Impella 5.5に対するFDA PMAを取得
米マサチューセッツ州ダンバース （ビジネスワイヤ） — アビオメッド（NASDAQ: ABMD）最新の心臓ポンプであるSmartAssist搭載Impella 5.5は、心原性ショックの最大14日までの治療の安全性と有効性が認められ、米国食品医薬品局（FDA）より市販前承認（PMA)を取得しました。...
View ArticleClik here to view.
Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy...
MALVERN, Pa, & TIANJIN, China Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on innovative therapies that address rare and underserved eye diseases, has entered...
View ArticleClik here to view.
AVITA Medical Announces Listing on Nasdaq
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in...
View ArticleClik here to view.
SIRION Biotech to Participate in Major International Industry Conferences
MARTINSRIED, Germany SIRION Biotech GmbH (“SIRION”) today announced its participation in major international conferences this October. SIRION, offering the most comprehensive portfolio of custom...
View ArticleClik here to view.
Kraig Biocraft Laboratories COO Travels to Vietnam to Assist Transition of...
ANN ARBOR, Mich. Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that Jon Rice, the Company’s chief operating officer,...
View ArticleClik here to view.
TCT 2019におけるPROTECT IIIの結果発表：ImpellaによるプロテクテッドPCIに転帰改善が伴うことを臨床データが証明
サンフランシスコ （ビジネスワイヤ） — アビオメッド（NASDAQ: ABMD）は、PROTECT III試験の結果を発表します。PROTECT IIIは、高リスクPCI患者でImpella 2.5およびImpella CPに対する市販後承認（PMA）を取得すべく進行中の前向き単群のFDA承認後試験で、PROTECT IIランダム化対照試験（RCT）に続くものです。...
View ArticleClik here to view.
NMPA Approves IND Application for CT103A, a Fully-human BCMA CAR-T for the...
NANJING, China IASO Biotherapeutics (IASO BIO), a clinical stage biotechnology company advancing the development of innovative therapies for cancer, and Innovent Biologics, Inc. (Innovent)...
View ArticleClik here to view.
Agilent Receives Approval for First PD-L1 Companion Diagnostic in China
SANTA CLARA, Calif. Agilent Technologies Inc. (NYSE: A) today announced that the National Medical Products Administration (NMPA, formerly the China Food and Drug Administration) has approved its...
View ArticleClik here to view.
Aroa Biosurgery Grows Into Additional Markets With Positive Outcomes From...
AUCKLAND, New Zealand Aroa Biosurgery, the Auckland-based privately held tissue-regeneration company, has this week presented positive outcomes of a new clinical study in Canada performed using its...
View ArticleClik here to view.
ザ エスティ ローダー カンパニーズ、2019年の乳がんキャンペーンで願いを込めて世界をつなぐ
ニューヨーク （ビジネスワイヤ） — 世界のどこかで15秒ごとに1人の女性が乳がんと診断されています1。そのため、1992年より、ザ エスティ ローダー カンパニーズは、乳がんのない世界を目指す乳がんキャンペーンにおいて、あらゆる地域の人々を結集させてプラスの影響を及ぼし、命を救うことに取り組んできました。27年にわたり、ザ エスティ ローダー...
View ArticleClik here to view.
NantHealth®, GE Healthcare, AirStrip and iProcedures Join Forces to Present...
BANGKOK & CULVER CITY, Calif. NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, announced today it will be presenting with GE Healthcare,...
View Article